Sorrento Therapeutics (NASDAQ: SRNE) is one of 306 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Sorrento Therapeutics to similar businesses based on the strength of its valuation, dividends, risk, profitability, analyst recommendations, institutional ownership and earnings.

Risk & Volatility

Sorrento Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics’ rivals have a beta of 1.39, suggesting that their average stock price is 39% more volatile than the S&P 500.

Institutional & Insider Ownership

15.8% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.0% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Sorrento Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sorrento Therapeutics -257.81% -95.98% -21.59%
Sorrento Therapeutics Competitors -5,380.19% -564.11% -42.16%

Valuation and Earnings

This table compares Sorrento Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Sorrento Therapeutics $8.15 million -$60.92 million -4.14
Sorrento Therapeutics Competitors $290.00 million $35.57 million 147.45

Sorrento Therapeutics’ rivals have higher revenue and earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Sorrento Therapeutics and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics 0 0 5 0 3.00
Sorrento Therapeutics Competitors 777 3094 11350 227 2.71

Sorrento Therapeutics presently has a consensus target price of $12.60, suggesting a potential upside of 375.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.29%. Given Sorrento Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Sorrento Therapeutics is more favorable than its rivals.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Receive News & Stock Ratings for Sorrento Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc. and related stocks with our FREE daily email newsletter.